Related Experiment Video

Updated: Jul 13, 2026

Telomere Length and Telomerase Activity; A Yin and Yang of Cell Senescence
12:08

Telomere Length and Telomerase Activity; A Yin and Yang of Cell Senescence

Published on: May 22, 2013

Statins and telomere length: risk assessment and management for coronary heart disease

Atul Tiwari1

  • 1Jubilant Biosys Ltd., Drug Discovery Unit-Biology, Bangalore 560022, Karnataka, India. atul_tiwari@jubilantbiosys.com

Expert Opinion on Therapeutic Targets
|July 7, 2007
PubMed

Insights

Biological ageing, indicated by shorter telomere length, increases coronary heart disease (CHD) risk. Statins may benefit patients with longer telomeres, suggesting personalized treatment approaches for CHD prevention.

Area of Science:

  • Cardiology
  • Gerontology
  • Molecular Biology

Background:

  • Coronary heart disease (CHD) is linked to biological ageing, distinct from chronological ageing.
  • Premature biological ageing increases susceptibility to myocardial infarction, atherosclerosis, and CHD.
  • Mean telomere length is a cellular marker for biological age; shorter telomeres indicate increased biological age.

Discussion:

  • Statins are standard for CHD and atherosclerosis treatment.
  • A clinical study found statin therapy reduced events only in individuals with increased risk, identified by telomere length.
  • This suggests telomere length is a predictor of statin efficacy in CHD patients.

Key Insights:

  • Shorter telomere length is associated with premature biological aging and elevated risk of coronary heart disease (CHD).
  • Telomere length correlates with the risk of CHD and atherosclerosis.
  • Statin treatment efficacy in reducing clinical events appears dependent on patient telomere length.

Outlook:

  • Telomere length measurement could enable personalized statin therapy for CHD patients.
  • Stratifying patients by leucocyte telomere length may optimize cardiovascular disease management and treatment strategies.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...